8-K
filed May 8, 2023, 7:59 PM ET
CIK 0001843762
other material
confidence high
sentiment negative
materiality 0.90
EQRx, Inc.: restructuring charge — EQRx resets strategy, terminates two license deals, cuts 170 jobs, posts $82.6M Q1 loss
EQRx, Inc.
- Terminates license agreements with CStone (sugemalimab/nofazinlimab) and Lynk (EQ121 JAK-1 inhibitor); partners regain rights outside Greater China.
- Approves restructuring: ~170 positions eliminated; estimated total restructuring costs $45M-$55M in 2023; expects annualized cash savings of at least $125M.
- Q1 2023 net loss $82.6M vs net income $20.7M in Q1 2022; cash and investments $1.3B; expects year-end cash ~$1.1B.
- Prioritizing lerociclib (CDK4/6 inhibitor) with Phase 3 trial in endometrial cancer; seeking partnerships for aumolertinib outside Greater China.
- Plans to separate early-stage immune-inflammatory programs into new subsidiary and explore its path as an independent company.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.85
EQRx, Inc. reported financial results for the first quarter ended March 31, 2023.
- Period
- the first quarter ended March 31, 2023
- Result
- reported results
Exact text from the filing
On May 8, 2023, EQRx issued a press release announcing its financial results for the first quarter ended March 31, 2023.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
EQRx, Inc. terminated Exclusive License Agreement with CStone Pharmaceuticals with CStone Pharmaceuticals valued at $150.0 million upfront non-refundable, non-creditable payment; additional potential milestone paymen (effective 2023-05-08).
- Action
- termination
- Agreement
- license
- Counterparty
- CStone Pharmaceuticals
- Value
- $150.0 million upfront non-refundable, non-creditable payment; additional potential milestone paymen
- Effective
- 2023-05-08
Exact text from the filing
Item 1.02 Termination of a Material Definitive Agreement. CStone Pharmaceuticals On May 8, 2023, EQRx, Inc. (EQRx) provided written notice to CStone Pharmaceuticals (CStone) of its termination of the Exclusive License Agreement dated October 26, 2020 between EQRx and CStone (as amended, the CStone Agreement), which termination will be effective in accordance with the terms of such agreement.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
EQRx, Inc. terminated Exclusive License Agreement with Lynk Pharmaceuticals with Lynk Pharmaceutical (Hangzhou) Co., Ltd. valued at Upfront non-refundable, non-creditable payment; additional potential milestone payments up to $172.0 (effective 2023-05-08).
- Action
- termination
- Agreement
- license
- Counterparty
- Lynk Pharmaceutical (Hangzhou) Co., Ltd.
- Value
- Upfront non-refundable, non-creditable payment; additional potential milestone payments up to $172.0
- Effective
- 2023-05-08
Exact text from the filing
On May 8, 2023, EQRx provided written notice to Lynk Pharmaceutical (Hangzhou) Co., Ltd. (Lynk) of its termination of the Exclusive License Agreement dated April 1, 2020 between EQRx and Lynk Pharmaceuticals (as amended, the Lynk Agreement), which termination will be effective in accordance with the terms of such agreement.
View on SEC.gov
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 0.9
EQRx, Inc. announced a restructuring with charges of in the range of $45.0 million to $55.0 million (a decrease in headcount of approximately 170 positions).
- Type
- restructuring
- Charge
- in the range of $45.0 million to $55.0 million
- Headcount
- a decrease in headcount of approximately 170 positions
Exact text from the filing
a result of, or that are associated with, the other May 2023 strategic decisions. Therefore, EQRx currently estimates total restructuring costs for 2023 will be in the range of $45.0 million to $55.0 million. Each departing employee of EQRx has played an integral role in EQRx’s commitment to develop and commercialize innovative medicines for some of the most
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.